Historical Review of the Use of Relative Risk Statistics in the Portrayal of the Purported Hazards of High LDL Cholesterol and the Benefits of Lipid-Lowering Therapy
The manner in which clinical trial investigators present their findings to healthcare providers and the public can have a substantial influence on their impact. For example, if a heart attack...
Conclusions/Relevance: We assert that the emphasis on RR coupled with insufficient disclosure of AR in the reporting of RCT outcomes has led healthcare providers and the public to overestimate concerns about high cholesterol and to be misled as to the magnitude of the benefits of cholesterol-lowering therapy. The goal of this review is to...
Share
Rare primary dyslipidaemias associated with low LDL and HDL cholesterol values in Portugal
Source : https://www.frontiersin.org/articles/10.3389/fgene.2022.1088040/full
Background: Dyslipidaemia represents a group of disorders of lipid metabolism, characterized by either an increase or decrease in lipid particles, usually associated with triglycerides, LDL cholesterol (LDL-C) and/or HDL cholesterol...
Conclusion: We report here the clinical and molecular characteristics of seven patients with rare lipid disorders associated with low LDL or low HDL. Two cases presented with hypoalphalipoproteinemia, and the genetic workup allowed the diagnosis of Tangier disease in one and of Fish Eye Disease in the other. These are ultrarare disorders,...
Share
Natural language processing to identify reasons for sex disparity in statin prescriptions
Source : https://www.sciencedirect.com/science/article/pii/S2666667723000375?via=ihub
Statins are the cornerstone of treatment of patients with atherosclerotic cardiovascular disease (ASCVD). Despite this, multiple studies have shown that women with ASCVD are less likely to be prescribed statins...
Conclusions: Women with ASCVD were less likely to be prescribed guideline-directed statins compared with men. NLP identified additional sex-based statin disparities and reasons for statin non-prescription in clinical notes of patients with ASCVD.
Share
Soluble PCSK9 Inhibition: Indications, Clinical Impact, New Molecular Insights and Practical Approach-Where Do We Stand? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37109259/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions/Relevance: Several clues suggest that regulation of PCSK9 represents a cornerstone of cardiovascular prevention, partly because of some pleiotropic effects attributed to these newly developed drugs. New mechanisms of PCSK9 regulation are being explored, and further efforts need to be put in place to reach patients with these new...
Share
Bruton's Tyrosine Kinase inhibition by Acalabrutinib does not affect early or advanced atherosclerotic plaque size and morphology in Ldlr-/- mice
Source : https://www.sciencedirect.com/science/article/pii/S1537189123000320?via=ihub
In human plaques, BTK is mainly expressed in mast cells, B cells and myeloid cells. * Acalabrutinib dose-dependently inhibits bone marrow-derived mast cell activation. * Acalabrutinib treatment does not affect...
Conclusions/Relevance: Conclusively, BTK inhibition by Acalabrutinib alone did neither affect either mast cell activation nor early- and advanced atherosclerosis, despite the effects on follicular B cell maturation.
Share